Bilayer Therapeutics
Cambridge, US · Founded 2020 · Delaware corporation · 1 known investors
Founders & leadership
TA
Thomas A. ColletExecutive
CT
Carlo Traverso GiovanniNamed on SEC filing
Board
RL
JK
Joshua KorzenikBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 2 rounds · 2021–2023
▶$300KraisedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$300KraisedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joshua KorzenikDirector
- Thomas A. ColletExecutive Officer, Director
- Robert LangerDirector
- Huang Yen-ChenDirector
- David ZhuDirector
- Carlo Giovanni TraversoDirector
- Offering amount
- $1M
- Amount sold
- $300K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2MraisedApr 2021 · 2 investors · BiotechnologyRule 506(b)
▶$2MraisedApr 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Carlo Traverso GiovanniDirector
- Joshua KorzenikDirector
- Thomas A. ColletExecutive Officer, Director
- Offering amount
- $3.6M
- Amount sold
- $2M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Bilayer Therapeutics's investors?
- Bilayer Therapeutics's investors include Kendall Capital Partners.
- How much funding has Bilayer Therapeutics raised?
- Bilayer Therapeutics has disclosed $2.3M raised across 2 rounds.
- Where is Bilayer Therapeutics headquartered?
- Bilayer Therapeutics is headquartered in Cambridge, US.